MOR202 (MOR03087)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MOR202 (MOR03087), covering 2021-10-28 to 2021-10-28. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]